Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) Research & Development (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Research & Development for 4 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • Quarterly Research & Development fell 41.23% to $3.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2025, down 37.35% year-over-year, with the annual reading at $18.7 million for FY2025, 37.35% down from the prior year.
  • Research & Development for Q3 2025 was $3.8 million at LENZ Therapeutics, down from $9.1 million in the prior quarter.
  • The five-year high for Research & Development was $18.5 million in Q4 2022, with the low at $3.8 million in Q3 2025.
  • Average Research & Development over 4 years is $11.5 million, with a median of $10.4 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 62.06% in 2024, then skyrocketed 30.47% in 2025.
  • Over 4 years, Research & Development stood at $18.5 million in 2022, then fell by 7.9% to $17.0 million in 2023, then crashed by 65.49% to $5.9 million in 2024, then plummeted by 35.4% to $3.8 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.8 million, $9.1 million, and $5.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.